Response Genetics to Provide GSK with PCR-Based BRAF Mutation Analysis
May 12, 2010
Response Genetics to Provide GSK with PCR-Based BRAF Mutation Analysis
GSK gains certain rights to Response Genetics' PCR analysis technology and diagnostic expertise to assess BRAF mutations in human tumor samples.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Response Genetics Raises $8.8M in Financing
September 13, 2012 / GenomeWeb Daily News - Abbott, GSK Add New Biomarker to Cancer Immunotherapy Companion Dx Agreement
December 1, 2011 / PCR Insider - Roche Launches Melanoma Companion Dx in EU After FDA OK Last Week
August 25, 2011 / PCR Insider - Abbott, GSK to Develop PCR-Based Molecular Dx to Select Patients for Trial Skin Cancer Therapy
March 4, 2010 / PCR Insider - GSK/Abbott Pen Rx/Dx Co-Development Deal for MAGE-A3 Non-Small Cell Lung Cancer Treatment
July 15, 2009 / Pharmacogenomics Reporter